Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.

We recently published These 10 Stocks are Winning Big. Vor Biopharma Inc. (NASDAQ:VOR) is one of the best-performing stocks on Monday. Vor Biopharma extended its winning streak to a fourth consecutive ...

US stocks moved higher on Tuesday, eyeing a bid for more records as investors combed through a fresh rush of corporate ...

Analysts’ view on the stock has dramatically changed over the past few months. Currently, only 21% of the 29 analysts ...

Realty Income Corporation (NYSE:O) is one of the stocks that Jim Cramer weighed in on. When a caller asked for Cramer’s ...

"This was primarily driven by 18% growth seen from the oncology portfolio, which has done well as a result of key drugs such ...

Shares of life sciences company Revvity (NYSE:RVTY) fell 7.6% in the afternoon session after the company lowered its ...

Sarepta Therapeutics (SRPT) shares dropped sharply on Monday following news that the FDA is investigating a patient death potentially connected to its gene therapy, Elevidys.

Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.

The Food & Drug Administration is investigating the death of an 8‑year‑old following Elevidys gene therapy for Duchenne ...

US stocks end up on earnings, data showing a resilient economy and trade deall optimism. S&P 500 and Nasdaq score records again.

View the latest Sarepta Therapeutics Inc. (SRPT) stock price, news, historical charts, analyst ratings and financial information from WSJ.